Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
NCT05050149
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Microcystic Lymphatic Malformation
Interventions
DRUG:
PTX-022
Sponsor
Palvella Therapeutics, Inc.